Article Figures & Data
Figures
- FIG. 1.
Kaplan-Meier analysis of the incidence of the first CMV DNA detection in PB cells and cardiac EMB samples from heart transplant recipients receiving anti-CMV prophylaxis. Results of qualPCR detection in PMNs (gray line), PBMCs (black line), and EMB specimens (dashed line) are shown.
- FIG. 2.
Differences in length of time to the first detection of CMV DNA based on cell type and CMV serostatus at transplant. (A) Time to first CMV detection in PBMCs versus PMNs in R+/D+ patients (P = 0.016 by Wilcoxon signed-rank paired analysis). (B) Time to first CMV detection in PBMCs versus PMNs in R−/D+ patients (P = 0.9 by Wilcoxon signed-rank paired analysis). (C) Time to first CMV detection in PBMCs versus PMNs in R+/D− patients (P = 0.5 by Wilcoxon signed-rank paired analysis). The thick line indicates the median, the lower and upper sides of the rectangles indicate 25th and 75th percentiles, respectively, and the bars indicate the 90th and 10th percentile limits.
- FIG. 3.
CMV DNA detection based on donor/recipient CMV serostatus at transplant. The Kaplan-Meier estimated incidence of CMV detection in PBMCs (A) or in PMNs (B) is shown. Determinations of the statistical significance of R+ and R−/D+ differences employed the log-rank test.
- FIG. 4.
Frequency of high-level CMV DNA in heart transplant recipients receiving anti-CMV prophylaxis. (A) Rate of samples showing >110 DNA copies/105 PMNs (high-grade infection) in the R−/D+ (open circles) and R+ (filled circles) patient groups over 16 months posttransplant. (Time periods were as follows: month 1, 14 to 45 days; month 2, 46 to 76 days; month 3, 77 to 105 days; month 4, 106 to 161 days; months 5 to 7, 162 to 208 days; months 8 to 10, 209 to 304 days; months 11 to 13, 305 to 426 days; months 14 to 16, 427 to 486 days). The standard prophylaxis period used for R+ patients is indicated by dark gray shading, and the aggressive prophylaxis period used for R−/D+ patients is indicated by light gray shading. (B) Distribution of patients developing low-grade (≤110 copies/105 cells) and high-grade (>110 copies/105 cells) infection according to CMV serological status.
Tables
- TABLE 1.
Baseline patient characteristics according to CMV DNA levels
No. of CMV DNA copies Recipient age (yr; P = 0.96)a,b Recipient gender (males/females; P = 0.61)c Donor age (yr; P = 0.95)b Donor gender (males/females; P = 0.77)c Cold ischemic time (min; P = 0.67)b Prophylaxis protocol (P = 0.04)c Standard (no. [%] of R+/D+ and R+/D− patients; P = 0.04)c Aggressive (no. [%] of R−/D+ patients) ≤110 (n = 46) 49 ± 14 35/11 33 ± 14 33/13 203 ± 44 28 (61) 18 (39) >110 (n = 20) 48 ± 15 14/6 32 ± 12 15/5 212 ± 57 17 (85) 3 (15)
